Showing results (541-550 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|October 9, 2007
Biotransformation and pharmacokinetics of the novel anticancer drug, SYUIQ-5, in the ratQi-Biao Su, Fan He, Xue-Ding Wang, et al.
Investigational New Drugs|October 10, 2007
The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitorKyle Holen, Leonard B Saltz, Ellen Hollywood, et al.
Investigational New Drugs|May 13, 2009
A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumorsAnne M Traynor, Michael S Gordon, Dona Alberti, et al.
Investigational New Drugs|April 25, 2009
Strong inhibition of replicative DNA synthesis in the developing rat cerebral cortex and glioma cells by roscovitineJuan Sebastian Yakisich, Marina Fernanda Vita, Ake Siden, et al.
Investigational New Drugs|April 25, 2009
Synthesis and in vitro characterization of ionone-based chalcones as novel antiandrogens effective against multiple clinically relevant androgen receptor mutantsJinming Zhou, Guoyan Geng, Jian Hui Wu
Investigational New Drugs|February 21, 2009
Primary systemic therapy with intermittent weekly paclitaxel plus gemcitabine in patients with stage II and III breast cancer: a phase II trialKeun Seok Lee, Jungsil Ro, Eun Sook Lee, et al.
Investigational New Drugs|April 10, 2009
The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapyK Dredge, E Hammond, K Davis, et al.
Investigational New Drugs|September 20, 2008
Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivoTashanna Myers, Shylet Chengedza, Stan Lightfoot, et al.
Investigational New Drugs|August 13, 2008
Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy)G Schilling, M Bruweleit, N Harbeck, et al.
Investigational New Drugs|August 12, 2009
The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II ConsortiumHalla S Nimeiri, Deepti A Singh, Kristen Kasza, et al.
Pageof 372